The β-thalassemias are a group of hereditary hematological diseases caused by over 300
mutations of the adult β-globin gene. Together with sickle cell anemia, thalassemia …

Hydroxyurea has long been used for the treatment of sickle cell anemia (SCA), and its
clinical effectiveness is related to the induction of fetal hemoglobin (HbF), a major modifier of …

Sickle cell disease (SCD) is a hemoglobinopathy that affects more than 100,000 individuals
in the United States. The disease is characterized by the presence of sickle hemoglobin and …

KLF1 regulates the γ-globin to β-globin genetic switch by many mechanisms. Firstly, it
facilitates formation of an active chromatin hub (ACH) at the β-globin gene cluster …

Hemoglobinopathies constitute the most common monogenic disorders worldwide, caused
by mutations in the globin genes that synthesize the globin chains of hemoglobin. Synthesis …

Hydroxyurea (HU) was approved to be used in the treatment of sickle cell disease (SCD)
because of its anti-sickling potential. However, there is variability in HU response among …

For decades, various strategies have been proposed to solve the enigma of
hemoglobinopathies, especially severe cases. However, most of them seem to be lagging in …

β‐hemoglobin disorders, such as β‐thalassemia and sickle cell anemia are among the most
prevalent inherited genetic disorders worldwide. These disorders are caused by mutations …

MicroRNAs (miRNAs) are small non-coding RNAs crucial for post-transcriptional and
translational regulation of cellular and developmental pathways. The study of miRNAs in …

Introduction: Hemoglobinopathies constitute the most common severe monogenic disorders
worldwide, with an increasing global burden each year. The benefit of applying programmes …